Press Releases
Jennerex to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
San Francisco, California, November 8, 2012 — Jennerex, Inc., a private, clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic immunotherapies, today announced that Laurent Fischer, M.D., the company's president and chief executive officer, is scheduled to present at the Lazard Capital Markets 9th Annual Healthcare Conference next week in New York City. The presentation is scheduled for Tuesday, November 13, 2012, at 9:00 a.m. ET.
This presentation will be available to interested parties through a live and archived audio webcast. To access the live and subsequently archived webcasts of the presentation, go to the Company's website at www.jennerex.org and go to "Events." Please connect to the website at least 15 minutes prior to the event to allow for any software download that may be necessary. The archived webcast will be available for seven days following the presentation.
About Jennerex
Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for cancer. The Company's lead product JX-594 is currently in an international, randomized Phase 2b clinical trial (TRAVERSE) in patients with advanced primary liver cancer who have failed sorafenib therapy. In addition, JX-594 is being tested in the same patient population in combination with sorafenib. JX-594 is also in a Phase 1/2 clinical trials in patients with treatment-refractory colorectal cancer. Published studies designed to establish optimal dose levels and the safety profile of JX-594 have shown its ability to selectively target and cause destruction of a variety of common solid tumor types and trigger a potent immune response. JX-594 and other product candidates under development are designed to attack cancer tumors through three diverse mechanisms of action: the lysis of cancer cells through targeted viral replication, the ablation of the blood supply to tumors and the stimulation of the body's immune response against the cancer. Jennerex is headquartered in San Francisco and has related research and development operations in Ottawa, Canada and Pusan, South Korea. For more information about Jennerex, please visit www.jennerex.org. For studies evaluating JX-594 please visit www.clinicaltrials.gov.
Back to Top
